Online inquiry

IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11967MR)

This product GTTS-WQ11967MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3&IGF1R gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005915.1; NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065; 3480
UniProt ID P21860; P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11967MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3370MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ10730MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ10306MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ14163MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ11909MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ457MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ2344MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AME-133v
GTTS-WQ13910MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN2477
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW